BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Agarwal SM, Panda R, Costa-Dookhan KA, MacKenzie NE, Treen QC, Caravaggio F, Hashim E, Leung G, Kirpalani A, Matheson K, Chintoh AF, Kramer CK, Voineskos AN, Graff-Guerrero A, Remington GJ, Hahn MK. Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial. Transl Psychiatry 2021;11:219. [PMID: 33854039 DOI: 10.1038/s41398-021-01338-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Dodd S, Sominsky L, Siskind D, Bortolasci CC, Carvalho AF, Maes M, Walker AJ, Walder K, Yung AR, Williams LJ, Myles H, Watson T, Berk M. The role of metformin as a treatment for neuropsychiatric illness. European Neuropsychopharmacology 2022;64:32-43. [DOI: 10.1016/j.euroneuro.2022.09.002] [Reference Citation Analysis]
2 Herman R, Kravos NA, Jensterle M, Janež A, Dolžan V. Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. Int J Mol Sci 2022;23:1264. [PMID: 35163187 DOI: 10.3390/ijms23031264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Schullerus M, Ruetz A, Reiff J, Braus DF. Psychotische Störungen, Antipsychotika und Diabetes. Diabetologe 2021;17:712-20. [DOI: 10.1007/s11428-021-00806-z] [Reference Citation Analysis]